Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Down – Here’s What Happened

Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) gapped down before the market opened on Friday . The stock had previously closed at $13.89, but opened at $13.19. Santen Pharmaceutical shares last traded at $13.19, with a volume of 180 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Santen Pharmaceutical Stock Down 5.0%

The stock’s 50-day simple moving average is $12.06 and its 200 day simple moving average is $11.35. The firm has a market cap of $4.25 billion and a P/E ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.